<DOC>
	<DOCNO>NCT00002809</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Combining chemotherapy radiation therapy together bone marrow transplant may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : This phase II trial study well give bone marrow transplant unrelated donor together cyclophosphamide total-body irradiation work treat patient hematologic cancer .</brief_summary>
	<brief_title>Bone Marrow Transplant Plus Cyclophosphamide Total-Body Irradiation Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Study curative potential high-dose cyclophosphamide total-body irradiation follow rescue bone marrow volunteer HLA-matched donor patient variety hematologic malignancy bone marrow failure state . - Study toxic effect associate match unrelated bone marrow transplantation patient population . - Participate collaborative research study National Marrow Donor Program . OUTLINE : All patient receive myeloablative therapy high-dose cyclophosphamide total body irradiation 4 day ; patient severe aplastic anemia also receive antithymocyte globulin . Patients undergo allogeneic bone marrow transplantation . Filgrastim ( G-CSF ) give transplant accelerate engraftment . Sargramostim ( GM-CSF ) may give case graft failure . All patient receive graft-versus-host-disease ( GVHD ) prophylaxis tacrolimus , methotrexate , gamma globulin . Established GVHD treat corticosteroid , necessary , antithymocyte globulin . Patients follow 100 day , 6 month , 1 year transplant , annually thereafter . PROJECTED ACCRUAL : A total 10 patient per year accrue study 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow hematologic malignancies/disorders : Acute lymphoblastic leukemia In second subsequent complete remission ( CR ) In first CR highrisk feature ( e.g. , Philadelphia chromosomepositive ) In first relapse fail conventional salvage therapy Acute myelogenous leukemia ( AML ) In second subsequent CR In early first relapse In full first relapse fail conventional salvage therapy In first CR highrisk feature , e.g. , trisomy 8 FAB 6/7 Standardrisk AML offer conventionaldose consolidation chemotherapy autologous bone marrow transplantation Chronic myelogenous leukemia chronic , accelerate , second chronic phase No blast crisis Severe aplastic anemia fail least 1 course immunosuppressive therapy Paroxysmal nocturnal hemoglobinuria highrisk feature ( e.g. , disseminate intravascular coagulation , thrombotic event ) Myelodysplastic syndrome , i.e . : Symptomatic , transfusiondependent refractory anemia excess blast ( RAEB ) RAEB transformation Secondary leukemia CR follow conventionaldose induction chemotherapy Unrelated marrow donor available 8 10 , 9 10 , 10 10antigen serologically HLAmatched A , B , C , DRb , DQB loci molecular type No CNS malignancy PATIENT CHARACTERISTICS : Age : 17 60 Performance status : Karnofsky 70100 % Life expectancy : No reduction due serious illness Hematopoietic : Not specify Hepatic : Bilirubin le 3 mg/dL AST/ALT great twice normal Renal : Creatinine great 2.0 mg/dL Creatinine clearance great 60 mL/min Cardiovascular : Left ventricular ejection fraction least 45 % No severe hypertension Pulmonary : DLCO , FEV_1 , FVC least 50 % Other : HIV negative No active infection time transplant No advance diabetes No significant neurologic deficit No active drug substance abuse No emotional disorder Able participate frequent medical care least 12 year Willing comply National Marrow Donor Program policy PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>